Kornimate/medical-research-clean huggingface dataset:
neoadjuvant immune checkpoint inhibitor combined with chemotherapy in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the primary object of this study is to determine tumor major pathological response (mpr) rate and pathologic complete response (pcr) rate in stage ib-iiia non-small cell lung cancer who subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy and molecular biomarkers related to the clinical response.


Eligibility criteria:
inclusion criteria: 1.able to understand the nature of this trial and provide written informed consent. 2.18 years ≤ age ≤ 80 years 3.histologically documented non-small cell lung cancer 4.nsclc with resection option for potential cure.this may include clinical stage ib, ii and iiia. 5.subjected to neoadjuvant immune checkpoint inhibitor combined with chemotherapy according to disease evaluation. 6.measurable disease by recist v1.1 7.tumor tissue sample and/or alveolar lavage fluid must be available for biomarker evaluation before operation. exclusion criteria: 1. subjects are excluded if they are enrolled in any other interventional studies. 2. administration of chemotherapy, device therapy or any other cancer therapy in 4 weeks before the study drug administration. 3. subjects are excluded if they have an active, known or suspected autoimmune disease requiring systemic treatment (e.g.corticosteroids or other immunosuppressive medications) in 2 years before the study drug administration. substitution therapy ( e.g. thyroxine, insulin) are permitted. 4. subjects with active concurrent malignancies are excluded i.e. cancers other than nsclc. 5. history of allergy to study drug components 6. any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results. 7. any other conditions that, in the investigator's opinion, unfit to attend this study.

Keywords: non-small cell lung cancer, neoadjuvant, biomarker
honey against sore throat

Conditions: Sore Throat; Honey

Summary: objective: the aim of this study is to investigate the symptomatic efficacy of oral use of different functional honeys in patients complaining of sore throat. materials and methods: in the preclinical phase of the study, a total of 1000 samples of honey were examined, and the honeys were subjected to physicochemical and microbiological analyses. based on their functional properties, five different groups of honey were determined. these are thyme honey with high antioxidant capacity, yüksekova with high antimicrobial activity, chestnut honey with high organic acid amount, linden honey with high enzymatic and pine honey with high anti-microbial, antioxidant and phenolic compounds and enzymes. in the clinical phase of the study, patients receiving conventional treatment were randomly assigned to receive either one of five different types of honey or a honey-like food product in addition to their treatment. they were instructed to use 15 grams twice daily for 10 days. patients were assessed on the 1st, 3rd, 7th, and 10th days for symptoms and complaints such as sore throat, difficulty swallowing, sensation of throat swelling, weakness, and fatigue.


Eligibility criteria:
inclusion criteria: adults presenting with sore throat symptoms due to an upper respiratory infection (uri) within the last four days were included in the study. a total of 300 patients over 18 years of age, who were prescribed necessary medication and exhibited signs and symptoms of sore throat, were enrolled. exclusion criteria: exclusion criteria included a history of diabetes, pollen or bee allergies, and aversion to honey. participants were required not to use any additional products outside of those provided by the researchers during the study period. written informed consent was obtained from all participants, who were then randomly assigned to either the study or control group.

Keywords: sore throat apitherapy functional honey
role of parasitic infection in inflammatory bowel disease and irritable bowel syndrome

Conditions: Parasite IBS IBD

Summary: role of parasitic infection in inflammatory bowel disease and irritable bowel the burden of the parasitic disease is in-direct relation with the health and nutritional status of the host, inducing not only parasite-specific immunity but also can modify the host's immune responses . many parasites can imitate inflammatory bowel disorders and some studies showed that infection with parasites can improve disorders like ibd or moderate the symptoms of inflammatory bowel disorders . even though, many studies have shown that gastrointestinal infection is an important risk factor for the development of ibs

1. detect the prevalence of parasite/s associated with inflammatory bowel diseases (ibd) and irritable bowel syndrome (ibs) in comparison with control subjects. 2. evaluating the effect of the parasite on the course and prognosis of the diseases. 3. evaluating the effect of the antiparasitic drugs on the course and prognosis of the diseases.

Eligibility criteria:
inclusion criteria: * diagnosis of ibd will be confirmed using 1. standard clinical, 2. endoscopic, 3. radiographic and4 pathological criteria according to the montreal classification of the extent and severity of ibd * diagnosis of ibs will depend on rome iv criteria 1. recurrent abdominal pain on average at least 1 day/week in the last 3 months, 2. associated with two or more of the following criteria: 3. related to defecation; 4. associated with a change in the frequency of stool and/ or associated with a change in the form (appearance) of stool. exclusion criteria: * any patient who received antipiotic or antiparasitic drug within the past 4 weeks
a study of mabthera (rituximab) in patients with rheumatoid arthritis who have had an inadequate response to a single anti-tnf inhibitor

Conditions: Rheumatoid Arthritis

Summary: this study will evaluate the efficacy and safety of mabthera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-tnf alpha inhibitor. mabthera-naive patients will be stratified into 3 arms, according to previous inadequate response to a)etanercept, b)infliximab or c)adalimumab. patients will be treated with mabthera (1g infusion) on day 1 and day 15, and will continue their basic methotrexate therapy. the anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * rheumatoid arthritis for \>=6 months; * previous inadequate response to a single anti-tnf alpha inhibitor; * methotrexate at a stable dose range 7.5-25 mg/week. exclusion criteria: * other chronic inflammatory articular disease or systemic autoimmune disease; * previous treatment with mabthera or intolerance to mabthera; * corticosteroids\>=10 mg/day prednisolone within last 2 weeks, or corticosteroids at unstable doses within last 2 weeks;
prospective assessment of symptoms and quality of life in rectal cancer patients receiving chemo-radiotherapy

Conditions: Rectal Cancer

Summary: prospective assessment of symptoms and quality of life in rectal cancer patients receiving chemo-radiotherapy.

study plan 1. only the principal investigator, sub-investigators, and research nurse will be approaching potential participants. the above listed also will be the only consentors for the study. the recruitment process will occur during the outpatient visits being held at the sidney kimmel comprehensive cancer center at johns hopkins. hipaa (health insurance portability and accountability act ) and guidelines and good clinical practice will be followed at all times to ensure that the privacy of participants included in the recruitment process are strictly guarded. 2. patients will be registered by the radiation oncology clinical subjects coordinator after eligibility is confirmed and informed consent is obtained. 3. the eortc (european organization for research and treatment of cancer)qlq- c30 (quality of life questionnaire), qlq-cr38 (quality of life questionnaire), and qlq-cr29 (quality of life questionnaire) forms will be completed by patients at the following time point: 1. within 3 weeks prior to start of radiotherapy 2. during the 4th week of radiotherapy (when treatment-related symptoms are expected to peak) 3. approximately one month after completion of radiotherapy during a follow-up visit 4. the qol forms (qlc-c30, qlq-cr38, and cr29) will be self-administered surveys. a nurse or other healthcare provider will be available to help the patient with any questions regarding the qol forms. 5. the symptom inventory will be collected in an interview by a nurse or other healthcare provider at the following time points: d. within 3 weeks prior to start of radiotherapy e. once weekly during radiotherapy f. approximately one month after completion of radiotherapy during a follow-up visit.

Eligibility criteria:
inclusion criteria: * all of the following questions must be answered "yes" for a patient to be eligible for this protocol. 1. is there a working diagnosis of rectal cancer? yes no 2. will the patient be receiving neoadjuvant concurrent chemotherapy and pelvic radiation? yes no 3. is the pelvic radiation planned for a dose of 45-54 gy and will it be delivered using a standard 3-field technique? yes no 4. is the patient ≥ 18 years of age? yes no 5. can the patient give informed consent? yes no exclusion criteria: * all of the following questions must be answered "no" for a patient to be eligible for this protocol. 1. has there been prior radiation to the pelvis? yes no 2. is the patient in the "special category" designated by the public health service (patients younger than 18, pregnant women, and prisoners)? yes no

Keywords: rectal cancer chemoradiation rectal cancer receiving chemoradiation.
mobilizing early management of mental health complications after mild traumatic brain injury

Conditions: Mild Traumatic Brain Injury

Summary: mental health problems frequently complicate recovery from mild traumatic brain injury (mtbi) but are under-recognized and under-treated. our research program aims to identify evidence-based strategies for closing this knowledge-practice gap. building on a successful pilot trial, the reseachers will evaluate the effectiveness of a clinical practice guideline implementation tool designed to support proactive management of mental health complications after mtbi in primary care.

goal: to determine if a clinical practice guideline implementation tool, designed to support proactive management of mental health complications, can improve clinical outcomes from mild traumatic brain injury (mtbi). background: up to 1 in 4 people who sustain an mtbi develop depression or an anxiety disorder within the first 3 months. mental health problems triple the risk of long-term disability after mtbi. however, mental health disorders after mtbi are under-detected and under-treated. canadian clinical practice guidelines for mtbi developed by the ontario neurotrauma foundation (onf) recommend that family physicians proactively screen and initiate treatment for mental health disorders. aims: to evaluate the effectiveness of an implementation intervention designed to facilitate timely detection and treatment of mental health complications in primary care. approach: triple-blinded (treatment provider, patient, assessor) cluster randomized controlled trial with two arms. the intervention involves collecting screening test results from patients and a complex intervention with two components: sharing the screening test results in an actionable format with their family physician and activating patients for the clinical encounter with the family physician by sharing education materials about mental health problems and treatment options after mtbi. the comparison group is usual care. hypotheses: the researchers hypothesize that the guideline implementation tool will be associated with lower rates of mental health complications at 26 weeks post-injury, compared to usual care.

Eligibility criteria:
inclusion criteria: * age 18-69 years old, * presentation to emergency department within 72 hours of injury, * probable mtbi diagnosis per emergency department chart review and interview based on world health organization neurotrauma task force diagnostic criteria, * fluent in english, * primary residence in british columbia, * designate a specific family physician or walk-in clinic where they plan to seek follow-up care exclusion criteria: * pre-existing unstable/serious medical condition (e.g., cancer, multiple sclerosis, etc.) * pre-existing unstable/severe mental illness (e.g., schizophrenia requiring hospital admission in past year)

Keywords: concussion
study to test the safety and immunogenicity of varivax (2007 process) (study v210-057) (completed)

Conditions: Varicella

Summary: this study will test the safety, tolerability, and immunogenicity of varivax manufactured with the 2007 commercial varicella-zoster virus (vzv) bulk process when concomitantly administered with m-m-r ii in healthy children.

this treatment has been approved for sale to the public.

Eligibility criteria:
inclusion criteria: * subject is in good health based on medical history * subject has no history of measles, mumps, rubella, chickenpox, or shingles exclusion criteria: * subject has previously received measles, mumps, rubella, and/or varicella vaccine either alone or in combination * subject has history of immune disorders * subject has been exposed to chickenpox/shingles, measles, mumps, rubella or varicella within 4 weeks of study start * subject has received an inactivated vaccine within 14 days of first dose of study vaccine * subject has received a live vaccine within 30 days of first dose of study vaccine * subject has received a blood transfusion or blood-derived products within 3 months of receiving study vaccine * subject has had a fever within 72 hours of study start
adelante: a randomized controlled trial to improve engagement in care for latinos with hiv

Conditions: HIV/AIDS

Summary: the goal of this study is to test the effectiveness of adelante on viral suppression among latinos with hiv and viral non-suppression. participants will receive adelante (5-session, community health worker-delivered, problem-solving intervention) or enhanced care condition (ecc, 5 reminder phone calls). we will evaluate the overall effectiveness of adelante compared with ecc on rates of viral suppression and emergency room visits and hospitalizations. our hypothesis is that adelante participants will achieve higher rates of viral suppression and will have lower rates of emergency room visits and hospitalizations compared with ecc at 12 months post-randomization.

participants will be latinx/hispanic individuals age ≥18 years who are at least 6 months since initiation of hiv treatment and have evidence of viral non-suppression (hiv rna ≥200 cpm). participants will be recruited from two ryan white-funded clinics in geographic priority areas in the us ending the hiv epidemic (ehe) plan due to high hiv incidences and prevalence. in the intervention, a bilingual (english-spanish speaking) community health worker (chw) will deliver a manualized problem-solving intervention that is framed around an hiv-focused telenovela, or drama-based film. the chw will deliver five sessions within 6 months. the chw will assist in problem-solving to improve behavioral activation and self-management skills and help participants adhere to hiv treatment and attend medical appointments. the chw will also link patients to resources. in the enhanced care condition, participants will receive 5 phone calls. they will not receive the intervention or access to navigation beyond routine care. measurements will occur at baseline, month-3, month-6, and month-12 post randomization by study staff blinded to the allocation status of participants. participants will be remunerated for each assessment.

Eligibility criteria:
inclusion criteria: * self-identify as latino/latina/latinx/hispanic; adults 18 years and over; with hiv infection confirmed by standard laboratory results available in the medical record; 6 or more months from initial entry into care with a medical provider who can prescribe hiv antiretroviral treatment; receiving hiv primary care at jackson memorial hospital or thomas street at quentin mease health center/harris health system; and medical record evidence with last viral load (vl) indicating viral non-suppression (hiv rna ≥200 cpm) within 12 months prior to assessment of eligibility, as it is typical for providers to obtain laboratories prior to a clinic visit in preparation for counseling. exclusion criteria: * lacks capacity to consent (measured by a validated screener), plans to move out of the county in the next 6 months, or currently participating in an hiv intervention study with ongoing follow-up.

Keywords: latino hispanic hiv/aids health outcomes community health worker
a novel technique of circumcision incision orchidopexy

Conditions: Cryptorchidism; Undescended Testis

Summary: given that both circumcision and orchidopexy are commonly done in a single setting, the investigators adopted the technique of orchidopexy via circumcision incision, particularly for palpable low inguinal cryptorchidism. in this paper, the investigators aim to present a novel technique and discuss our preliminary outcome of such procedure compared to the traditional inguinal-scrotal double incision technique. specifically, the investigators aimed to determine the differences in operative time, testicular size changes, peri-operative complications, pain score and parent's satisfaction of both novel technique and conventional orchidopexy.

cryptorchidism is the most common disorder of the male endocrine gland in children.. 1 according to the latest guideline by european association of urology in the pediatric urology for the treatment of cryptorchidism, both inguinal and scrotal approaches orchidopexy are accepted standard treatment options. 2 in the local setting, circumcision is another common surgical procedure among the children, particularly under the same instance of anesthesia for other procedure. not only due to religious and sociocultural reasons, male circumcision has been recently considered having a protective effect against acquisition of various sexually transmitted infections (stis). 3 this benefit is one of many that have led to many affirmative evidence-based policy statements by medical bodies in support of the procedure. given that both procedures are commonly done in a single setting, we adopted the technique of orchidopexy via circumcision incision, particularly for palpable low inguinal cryptorchidism. in this paper, we aim to present a novel technique and discuss our preliminary outcome of such procedure compared to the traditional inguinal-scrotal double incision technique. specifically, we aimed to determine the differences in operative time, testicular size changes, peri-operative complications, pain score and parent's satisfaction of both novel technique and conventional orchidopexy.

Eligibility criteria:
inclusion criteria: * children diagnosed with palpable cryptorchidism with pre-operative inguino-scrotal ultrasound to confirm the location of the testis on the low inguinal canal and its viability. exclusion criteria: * excluded were non-palpable testis, with prior orchidopexy, circumcised, with other concomitant genital anomalies.
mi-bp: mhealth to improve blood pressure control

Conditions: Hypertension

Summary: this study seeks to evaluate a multicomponent mobile intervention to change multiple hypertension-related health behaviors in minorities and the underserved with uncontrolled hypertension. half of the participants will receive a mobile intervention designed to improve physical activity, sodium intake, and medication adherence. the other half will receive usual care.


Eligibility criteria:
inclusion criteria: * detroit-area residents * hypertensive * owning a compatible smartphone * presenting to the detroit medical center detroit receiving, sinai-grace hospital, or selected community health screening events with, but not necessarily for, uncontrolled blood pressure (systolic blood pressure ≥ 135 mm hg at triage and on repeat measurement using the bptru device). exclusion criteria: * no self-reported prior history of hypertension * no hypertension diagnosis documented in their medical record * non-english speaking * presenting with an acute illness necessitating immediate medical intervention * presenting with an admission to the hospital for critical reasons (as determined by the attending physician) * pregnant (as determined by a dip test at screening), or self-report during trial. * having the following serious comorbidities or confounders due to the fact that they may make blood pressure control difficult or necessitate frequent emergency department use or hospitalization: * previous diagnosis of resistant hypertension (or current use of 3 or more maximally dosed antihypertensive agents without achievement of blood pressure control) * steroid dependent asthma or emphysema * cirrhosis or hepatic failure * chronic heart failure (any stage) * previous diagnosis of acute myocardial infarction, angina (stable or unstable), or known coronary artery disease * previous diagnosis of cerebrovascular disease (including transient ischemic attack or stroke) * known valvular heart disease * stage iv or v chronic kidney disease * cancer (terminal or undergoing active chemotherapeutic or radiation therapy) * patients with other serious medical conditions that may affect their ability to self-monitor blood pressure (such a dementia) * having a history of alcohol or drug abuse as determined by the cage-aid questionnaire (excluded if 2 or more) * week 2 measurement of systolic blood pressure \< 130 mm hg using the bptru device or study-issued bp cuff.

Keywords: hypertension mhealth